Henan Tianfu Chemical Co., Ltd.

Pharmaceutical Agrochemicals Food Additives Synthetic Flavours & Fragrances Plant Extract Adhesive and Sealant Catalyst and Auxiliary Dyestuff and Pigment Materials Basic Inorganic Chemicals Organic Chemicals Others Reagent

Henan Tianfu Chemical Co., Ltd.

Country: China (Mainland)Business Type: Lab/Research institutions

Manufacturer

Assessed supplierAssessed
supplier

qq

    x
  • Mr.Nolan
  • Ms. Jane Kong

Contact US
Mr.Anson
Tel: 86-371-55170693/55170694
Ms.Fan Cindy
Tel: +86 0371 5517 0693
Mr.Richard Ran
Tel: 86 371 55170693
Ms.Anna
Tel: +86 -371 5517 0693
Mr.Nolan
Tel: 0371-55170695
Mr.Jeff Pei
Tel: 0371-55170693
Ms.Alice
Tel: :+86-371-5517 0693
Mr.Anson
Tel: 0371-55170693-8638
Ms.Monica Xie
Tel: 86 0371 5517 0693(147)
Ms.Cherry Zhang
Tel: 0086-371-55170690
Ms.Daisy He
Tel: 371-55170693
  • Fax: 86-371-55170690
  • URL: http://www.tianfuchem.com
  • Province/state: Henan
  • City: Zhengzhou
  • Street:Zhengzhou International Trade New Territory,Jinshui District,Zhengzhou ,China
  • MaxCard:
Home > Products > 

88852-12-4 Limaprost

88852-12-4 Limaprost CAS NO.88852-12-4

  • FOB Price: USD: 500.00-500.00 /Kilogram Get Latest Price
  • Min.Order: 1 Kilogram
  • Payment Terms: L/C,T/T,
  • Available Specifications:

    A(10-15)Kilogram

  • Product Details

Keywords

  • 88852-12-4 Limaprost
  • 88852-12-4 Limaprost
  • 88852-12-4 Limaprost

Quick Details

  • ProName: 88852-12-4 Limaprost
  • CasNo: 88852-12-4
  • Appearance: Powder
  • Application: Organic Chemicals
  • DeliveryTime: according to client's demand quantity
  • PackAge: as requested
  • Port: SHANGHAI
  • ProductionCapacity: 100 Metric Ton/Day
  • Purity: 99%
  • Storage: room temperature
  • Transportation: by sea
  • LimitNum: 1 Kilogram
  • Heavy metal: 10ppm
  • Grade: Industrial Grade,Pharma Grade
  • Transportation: LCL

Superiority

Product Name: Limaprost
Synonyms: 17S,20-Dimethyl-trans-D2-PGE1 compd. with a-cyclodextrin;2,4,7,9,12,14,17,19,22,24,27,29-Dodecaoxaheptacyclo[26.2.2.23,6.28,11.213,16.218,21.223,26]dotetracontane, a-cyclodextrin deriv.;2-Heptenoic acid, 7-[(1R,2R,3R)-3-hydroxy-2-[(1E,3S,5S)-3-hydroxy-5-methyl-1-nonenyl]-5-oxocyclopentyl]-, (2E)-, compd. with a-cyclodextrin (9CI);a-Cyclodextrin, compd. with (2E)-7-[(1R,2R,3R)-3-hydroxy-2-[(1E,3S,5S)-3-hydroxy-5-methyl-1-nonenyl]-5-oxocyclopentyl]-2-heptenoic acid (9CI);a-Cyclodextrin, compd. with (2E,11a,13E,15S,17S)-11,15-dihydroxy-17,20-dimethyl-9-oxoprosta-2,13-dien-1-oic acid;Limaprost a-cyclodextrin clathrate;limaprost alfadex;OP 1206-a-cyclodextrin
CAS: 88852-12-4
MF: C36H60O30.C22H36O5
MW: 1353.36
EINECS:
Product Categories:
Mol File: 88852-12-4.mol

Limaprost Usage And Synthesis
Description Limaprost is an orally-active antithrombotic and vasodilator structurally related to alprostadil. Oral administration of limaprost causes a dose-dependent inhibition of platelet aggregation, an increase in platelet CAMP and a mild suppression of platelet adhesiveness. In patients with pulmonary emphysema, tuberculosis, and chronic lung disease, treatment with limaprost reportedly produces significant cardiac improvements.

Details

Product Name: Limaprost
Synonyms: 17S,20-Dimethyl-trans-D2-PGE1 compd. with a-cyclodextrin;2,4,7,9,12,14,17,19,22,24,27,29-Dodecaoxaheptacyclo[26.2.2.23,6.28,11.213,16.218,21.223,26]dotetracontane, a-cyclodextrin deriv.;2-Heptenoic acid, 7-[(1R,2R,3R)-3-hydroxy-2-[(1E,3S,5S)-3-hydroxy-5-methyl-1-nonenyl]-5-oxocyclopentyl]-, (2E)-, compd. with a-cyclodextrin (9CI);a-Cyclodextrin, compd. with (2E)-7-[(1R,2R,3R)-3-hydroxy-2-[(1E,3S,5S)-3-hydroxy-5-methyl-1-nonenyl]-5-oxocyclopentyl]-2-heptenoic acid (9CI);a-Cyclodextrin, compd. with (2E,11a,13E,15S,17S)-11,15-dihydroxy-17,20-dimethyl-9-oxoprosta-2,13-dien-1-oic acid;Limaprost a-cyclodextrin clathrate;limaprost alfadex;OP 1206-a-cyclodextrin
CAS: 88852-12-4
MF: C36H60O30.C22H36O5
MW: 1353.36
EINECS:
Product Categories:
Mol File: 88852-12-4.mol

Limaprost Usage And Synthesis
Description Limaprost is an orally-active antithrombotic and vasodilator structurally related to alprostadil. Oral administration of limaprost causes a dose-dependent inhibition of platelet aggregation, an increase in platelet CAMP and a mild suppression of platelet adhesiveness. In patients with pulmonary emphysema, tuberculosis, and chronic lung disease, treatment with limaprost reportedly produces significant cardiac improvements.

Other products of this supplier